New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Neurocrine Biosciences, Inc.
NBIX
Shape
US Flag

NASDAQ

12B

Drug Manufacturers - Specialty & Generic

Next Earning date - 30 Oct 2024

12B

Drug Manufacturers - Specialty & Generic

Next Earning date - 30 Oct 2024

116.08USD
Shape0.56 ( 0.48%)
favorite-chart

Relative Strenght

84
favorite-chart

Volume Buzz

8%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

27%

Quote Panel

Shape
Updated October 27, 2024
1W -0.42 % 1M 0.75 % 3M -20.08 % 1Y 8.35 %

Key Metrics

Shape
  • Market Cap

    11.72B


  • Shares Outstanding

    100.98M


  • Share in Float

    98.78M


  • Dividende

    0


  • Earning Date

    30 Oct 2024


  • Price Target

    116.08


  • Average Volume

    936076


  • Beta

    0.364


  • Range

    103.63-157.98


  • Industry

    Drug Manufacturers - Specialty & Generic


  • Website

    https://www.neurocrine.com


  • Sector

    Healthcare


Fundamentals

Shape

35.07x

P/E Ratio

5.53x

P/S Ratio

4.66x

P/B Ratio

0.1

Debt/Equity

16.0%

Net Margin

$3.3

EPS

How NBIX compares to sector?

P/E Ratio

Relative Strength

Shape

NBIX

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$3B

Shape360%

2025-Revenue

$6.59

Shape930%

2025-EPS

$637M

Shape310%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Piper Sandler

upgrade

Previous: Not converted

2024-08-29

Now: Overweight

Wells Fargo

upgrade

Previous: Buy

2024-04-23

Now: Overweight

Leerink Partners

upgrade

Previous: Not converted

2023-07-24

Now: Outperform

MoffettNathanson

upgrade

Previous: Not converted

2023-07-24

Now: Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+200%

0.69
vs 0.23

Q4.22

arrow
arrow

+1200%

0.88
vs -0.08

Q1.23

arrow
arrow

N/A

-0.79
vs 0.14

Q2.23

arrow
arrow

+628%

0.95
vs -0.18

Q3.23

arrow
arrow

+19%

0.82
vs 0.69

Q4.23

arrow
arrow

+64%

1.44
vs 0.88

Q1.24

arrow
arrow

+153%

0.42
vs -0.79

Q2.24

arrow
arrow

-34%

0.63
vs 0.95

Q3.24

arrow
arrow

+85%

1.52
vs 0.82

Q4.24

arrow
arrow

+11%

1.59
vs 1.44

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+31%

387.9M  vs 296M

Q4.22

arrow
arrow

+32%

412M  vs 312M

Q1.23

arrow
arrow

+35%

420.4M  vs 310.6M

Q2.23

arrow
arrow

+20%

452.7M  vs 378.2M

Q3.23

arrow
arrow

+29%

498.8M  vs 387.9M

Q4.23

arrow
arrow

+25%

515.2M  vs 412M

Q1.24

arrow
arrow

+23%

515.3M  vs 420.4M

Q2.24

arrow
arrow

+30%

590.2M  vs 452.7M

Q3.24

arrow
arrow

+20%

600.6M  vs 498.8M

Q4.24

arrow
arrow

+21%

621.5M  vs 515.2M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

+4%

0.04
vs -0.01

Q4.22

arrow
arrow

+5%

0.05
vs 0.04

Q1.23

arrow
arrow

-5%

-0.05
vs 0.05

Q2.23

arrow
arrow

+5%

0.05
vs -0.05

Q3.23

arrow
arrow

+4%

0.04
vs 0.05

Q4.23

arrow
arrow

+7%

0.07
vs 0.04

Q1.24

arrow
arrow

+2%

0.02
vs 0.07

Q2.24

arrow
arrow

+3%

0.03
vs 0.02

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

466

466
vs 441

6%

Q4.22

arrow
arrow

533

533
vs 466

14%

Q1.23

arrow
arrow

490

490
vs 533

-8%

Q2.23

arrow
arrow

461

461
vs 490

-6%

Q3.23

arrow
arrow

522

522
vs 461

13%

Q4.23

arrow
arrow

557

557
vs 522

7%

Q1.24

arrow
arrow

601

601
vs 557

8%

Q2.24

arrow
arrow

596

596
vs 601

-1%

Earnings Growth

Latest News